Basiliximab, sold under the brand name Simulect, is a monoclonal antibody used to prevent rejection in kidney transplants. [2][3] It is a chimeric mouse-human monoclonal antibody to the …

Sep 24, 2024 · What is basiliximab? Basiliximab is used with other medications to prevent organ rejection after a kidney transplant. Basiliximab weakens your immune system to prevent your …

Jun 13, 2005 · Basiliximab is a monoclonal anti-C25 antibody (interleukin-2 receptor alpha subunit) used as immunosuppressive therapy in kidney transplant patients.

Basiliximab injection is used with other medications to prevent immediate transplant rejection (attack of the transplanted organ by the immune system of the person receiving the organ) in …

Jan 31, 2024 · Basiliximab works by preventing the white blood cells from getting rid of the transplanted kidney. The effect of basiliximab on the white blood cells may also reduce the …

Jul 19, 2022 · Simulect ® (basiliximab) is indicated for the prophylaxis of acute organ rejection in patients receiving renal transplantation when used as part of an immunosuppressive regimen …

Feb 17, 2020 · Basiliximab is a chimeric (murine/human) immunosuppressant monoclonal antibody which blocks the alpha-chain of the interleukin-2 (IL-2) receptor complex; this …

Basiliximab stops your body from rejecting a transplanted kidney. A kidney transplant is a procedure where a new donor kidney is placed in your body. This medication is an injection …

May 10, 2024 · Immunosuppressive agent; recombinant DNA-derived chimeric (human-murine) monoclonal antibody. Prevention of renal allograft rejection. Manufacturer recommends use in …

Basiliximab is a prescription medication used to prevent organ rejection after a kidney transplant. Basiliximab is available under the following different brand names: Simulect